VEEV

TentativeAI MemoPost-earnings T+1

Veeva

As of 2026-08-27/Post-earnings T+1/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-27 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 FY27 beat and updated outlook • 2026-08-27

Base target: $300 / p=50% prob

Biggest risk

The stock had already rallied sharply before earnings and now trades above the packet's pre-print $255 median analyst target. A high post-print expectation bar leaves downside if Falcon monetization, CRM conversion, or R&D growth fail to accelerate.

Invalidation

Break below $235 or thesis failure.

What would change my mind?

The earnings print was a clear beat on revenue and EPS, management's full-year view improved, and Jefferies reportedly raised its target to $295 from $250 while maintaining Buy. CRM wins, AI adoption, and Falcon interest strengthen the forward narrative.

Research note

Recommendation

—

Confidence

high

As of

2026-08-27

Base target

$300

p=50%

Bull target

$330

p=25%

Bear target

$235

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-earnings valuation digestion
Vault CRM and AI/Falcon adoption
The earnings print was a clear beat on revenue and EPS, management's full-year view improved, and Jefferies reportedly raised its target to $295 from $250 while maintaining Buy.

BearKey bullets

AI and Falcon adoption may take longer to monetize than expected, despite early-adopter progress.
[#IR-2026-08-26]
An officer disclosed August 13 open-market sales totaling approximately 36,000 shares; this is an insider-activity signal only and not evidence of operating deterioration.

WatchKey bullets

Q2 FY27 beat and updated outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+1

Base case: $300 (p=50%)

Target spread vs base: +10% / -22%

Scenario probabilities

Bull Target: $330 (p=25%)Base Target: $300 (p=50%)Bear Target: $235 (p=25%)

Commentary

News tone is strongly positive after the Q2 beat, updated outlook, and reported analyst target increase. The shares were up approximately 17.5% on August 27 from the prior close. Social coverage was unavailable. The revised peer set includes direct competitors identified in Veeva's 10-K, but no comparable operating or valuation metrics were available; confidence is high on the earnings event but lower on incremental upside after the repricing.

As of 2026-08-27 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-earnings valuation digestion
Vault CRM and AI/Falcon adoption

Scenarios

Bull Target (Scenario probability)

$330 / p=25% prob

Base Target (Scenario probability)

$300 / p=50% prob

Bear Target (Scenario probability)

$235 / p=25% prob

Analysis 2026-08-27 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.78

Social Sentiment (7d)

0.50

Events

Other notable items detected

EVENT2026-08-27
Q2 FY27 beat and updated outlook
Veeva reported Q2 revenue of $928.0M, subscription revenue of $766.8M, and non-GAAP EPS of $2.35; stored pre-release estimates were $904.07M revenue and $2.22 EPS. Management provided Q3 revenue guidance of $932-$935M and updated FY27 revenue guidance of $3.682-$3.687B. The release was furnished with the SEC 8-K. [#IR-2026-08-26] [#SEC-8K-2026-08-26] [#PR-EARNINGS-2026-08-21]
Prob 95.00% • Move 17.50% • Priced-in 90.00%

Short-term Catalysts

Next few weeks

Post-earnings valuation digestion
2026-09-30
The shares rose to approximately $287.83 on August 27 from the $244.91 August 26 anchor, after a strong prior-month rally. The move leaves less room for execution misses or slower AI monetization, creating a near-term consolidation risk.
Prob 45% • Move -8% • Priced-in 80%

Long-term Catalysts

Months to a year

Vault CRM and AI/Falcon adoption
2026-12-31
Veeva reported more than 180 Vault CRM customers live, 12 top-20 biopharma commitments, five Falcon early adopters, and initial Falcon go-lives targeted for 2026. Execution on these milestones could support durable growth, but commercialization remains forward-looking. [#IR-2026-08-26]
Prob 70% • Move 12% • Priced-in 65%

Risks

AI and Falcon adoption may take longer to monetize than expected, despite early-adopter progress. [#IR-2026-08-26]
An officer disclosed August 13 open-market sales totaling approximately 36,000 shares; this is an insider-activity signal only and not evidence of operating deterioration. [#SEC-FORM4-2026-08-17]
Customer priorities, competitive pressure, life-sciences funding or policy changes, macro conditions, and product security or privacy issues could affect growth. [#IR-2026-08-26]
The sharp post-earnings move increases multiple-compression and profit-taking risk.

Peers

Symbol	Summary
IQV	Direct operating comparator: Veeva's FY2026 10-K identifies IQVIA as competing in Commercial CRM, data products, and certain Development and Quality applications. The comparison remains qualitative because no peer operating metrics were supplied. [#10-K-2026-03-20]
CRM	Direct operating comparator: Veeva's FY2026 10-K identifies Salesforce as its primary CRM competitor and notes Salesforce's life-sciences-specific CRM offering. The comparison remains qualitative because no peer operating metrics were supplied. [#10-K-2026-03-20]

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-27

Loading AI feed…

Symbol

Summary

IQV

Direct operating comparator: Veeva's FY2026 10-K identifies IQVIA as competing in Commercial CRM, data products, and certain Development and Quality applications. The comparison remains qualitative because no peer operating metrics were supplied. [#10-K-2026-03-20]

CRM

Direct operating comparator: Veeva's FY2026 10-K identifies Salesforce as its primary CRM competitor and notes Salesforce's life-sciences-specific CRM offering. The comparison remains qualitative because no peer operating metrics were supplied. [#10-K-2026-03-20]